Kornimate/medical-research-clean huggingface dataset:
modified rapid sequence induction in morbidly obese patients

Conditions: Anesthesia Intubation Complication

Summary: this study investigates the effect of 4 different methods of rapid sequence induction (rsi) in morbidly obese patients on the amount of air insufflation into the stomach.

100 adult patients with a body mass index \> 40 undergoing elective laparoscopic surgery will be included. patients with a history of previous bariatric surgery or with an anticipated difficult airway will be excluded. the randomization will be 1:1:1:1 stratified for gastro-esophageal reflux disease. all groups will receive standardized preoperative continuous positive airway pressure (cpap) therapy. in the operation theater, group one will receive pre-oxygenation for 3 minutes via a tight fitting face mask without positive end-expiratory pressure (peep). induction agents will be administered as quick boluses (propofol 2,5mg/kg total body weight, max 350mg, fentanyl 250mcg, rocuronium 1,2mg/kg ideal body weight) and tracheal intubation will be performed after 1 minute. no bag mask ventilation will be performed in-between. group 2 will receive pre-oxygenation via a tight face mask with a peep of 10 mbar for 3 minutes. the same induction agents as in group one will be administered. peep via facemask will be continued for one minute and tracheal intubation will be performed. group 3 will receive pre-oxygenation via a tight fitting facemask with a peep of 10 mbar with additional pressure support of 8 mbar and a back up ventilation frequency will be set to 10/min. after the same induction agents are given as in group 1, patients will receive non-invasive ventilation via ventilator at the settings described earlier for group 3. group 4 will receive the same induction as group 3, in addition a cricoid pressure will be applied during the non invasive ventilation.

Eligibility criteria:
inclusion criteria: * bmi \> 40 * american society of anesthesiology class 1-3 * elective laparoscopic surgery exclusion criteria: * pregnant or breastfeeding patients * previous bariatric surgery * anticipated difficult airway
contraceptive pills and retinal vascularization

Conditions: Combined Oral Contraceptives Intake

Summary: the main hypothesis is the taking of combined 1st and 2nd generation or 3rd and 4th generation oral contraceptives is associated with a change in retinal micro-vascularization compared to the absence of combined oral contraceptive intake. women of childbearing age will be recruited during their ophthalmologic consultation at the rothschild foundation, an oct-a will be realized and data relating to their medical and ophthalmologic history and their oestro-progestative contraceptive intake will be collected. the objective is to find an association between retinal vascular density and combined oral contraceptives intake.


Eligibility criteria:
inclusion criteria * for the control group : no estro-progestin contraceptive treatment (oral, transdermal) for at least 6 months * for the cases under combined 1st and 2nd generation pills : estro-progestin contraceptive treatment for at least 6 months * for the cases under combined 3rd and 2th generation pills: estro-progestin contraceptive treatment for at least 6 months exclusion criteria: * menopausal woman * ametropia greater than + 3 hyperopia diopters or-3 myopia diopters * astigmatism greater than 2 dioptres * smoking patient (cigarette or e-cigarette) * caffeine intake within 2 hours prior to the oct-a exam * any known retinal pathology * antecedent of deep vein thrombosis or deep arterial thrombosis

Keywords: oct-a combined oral contraceptives
hyperactivity assessment in children with attention-deficit hyperactivity disorder

Conditions: Attention Deficit Disorder With Hyperactivity

Summary: attention-deficit hyperactivity disorder (adhd) is a neurodevelopmental disorder characterized by inattention, hyperactivity, and impulsivity. clinical diagnosis of this disorder depends of history taking, parent report, and questionnaire. attention test such as continuous performance test can provide quantitative measurement on attention deficits; however, there is a lack of objective tool to quantify the activity level. this study aims to assess activity level in children with adhd. we plan to recruit 50 children with adhd and 50 neurotypical children. the activity level measured by wearable device will be compared between adhd and neurotypical children. the correlation between behavior rating on questionnaire and quantitative data measured by wearable device will be analyzed.


Eligibility criteria:
adhd group: inclusion criteria: * dsm-5 attention-deficit hyperactivity disorder * 7\~18 years old * willing to carry smartwatch and smartphone most of the time during one-month study period exclusion criteria: * comorbid with major psychiatric disorders (i.e., schizophrenia, bipolar disorder) or neurodevelopmental disorders (i.e., intellectual disability, autism spectrum disorder) * unable to use smartwatch and smartphone neurotypical group: inclusion criteria: * 7\~18 years old without a diagnosis of attention-deficit hyperactivity disorder * willing to carry smartwatch and smartphone most of the time during one-month study period exclusion criteria: * have a diagnosis of major psychiatric disorders (i.e., schizophrenia, bipolar disorder) or neurodevelopmental disorders (i.e., intellectual disability, autism spectrum disorder) * unable to use smartwatch and smartphone
the effect of anti-gravity treadmill training in patients with meniscus tears

Conditions: Meniscus Tear

Summary: the aim of this study is to evaluate the effect of anti-gravity treadmill training on symptoms and functions in patients with meniscus tears.

meniscus tears are one of the most common sports-related injuries. acute trauma-related tears are more common in active young individuals and athletes. symptoms such as pain, effusion, tenderness at the joint line, locking, and knee dysfunction are observed after injury. it is aimed to provide painless movement, normal knee kinematics, and retaining of muscle strength in rehabilitation process. anti-gravity treadmills use an inflatable space around the lower extremities and significantly reduce body weight during walking and running. anti-gravity treadmill training protects the joint and surrounding soft tissues against the negative effects of loading during the post-injury recovery process, and allows the tissues to heal safely. the aim of this study is to evaluate the effect of anti-gravity treadmill training on symptoms and functions in patients with meniscus tears. patients will be randomly divided into three groups: anti-gravity treadmill group, conventional treadmill group, and control group. all patients will be included physiotherapy and rehabilitation program for 6 weeks, 2 days a week. while subjects in the anti-gravity treadmill group will participate to training anti-gravity treadmill walking, subjects in the conventional treadmill group will participate walking program on a standard treadmill. symptoms and functions will be assessed baseline and after 6-week program.

Eligibility criteria:
inclusion criteria: * age between 18-40 years old * clinical history and symptoms consistent with mri-confirmed meniscus tear exclusion criteria: * history of previous knee surgery * other knee ligament pathologies * neurological disorders

Keywords: meniscus anti-gravity exercise
non invasive neurostimulation technology for the treatment of type i complex regional pain syndrome (crps i)

Conditions: Type I Complex Regional Pain Syndrome

Summary: complex regional pain syndrome (crps) / complex regional pain syndrome (crps) is a chronic neurological disorder that affects the extremities and is characterized by disabling pain, swelling, vasomotor instability, sudomotor abnormality, and impaired motor function; the duration and clinical magnitude is greater than expected, being divided into three stages of progression over time: stage i: acute (0-3 months); stage ii: dystrophic (3-9 months); stage 3: atrophic (9-18 months). the purpose of this study is to investigate the effect on complex pain syndrome using a conventional care protocol plus the application of non-invasive neuromodulation during compared to the effect of the same protocol plus placebo.

the design of this study is a randomised, triple blind clinical trial with placebo control. the size of the sample will be 42 participants who come to referral hospitals. they will be randomized in two groups: control or experimental. the variables of the study will be collected at three time points: before the intervention, during the intervention and at the end of the intervention. the variables of the study will be collected at two time points: before the intervention and at the end of the intervention. the statistical analysis will be an intention-to-treat analysis. for the main outcomes variables a two factor anova will-be performed (intervention-time) with a post-hoc analysis with kruskal wallis correction correction. statistical significance will be defined as p \<0.05

Eligibility criteria:
inclusion criteria: * meet the budapest criteria for the clinical diagnosis of crps type i. * age between 18 and 65. * period between 0 and 6 months after the onset of the clinical picture. * have signed the informed consent of their own free will. exclusion criteria: * have a diagnosis of crps type ii. * present type i crps in more than one limb. * patients who have suffered a recurrence of crps type i. * pregnancy or plans for it during the study. * previous sympathectomy in the affected limb.

Keywords: physical therapy modality electric stimulation therapy pain
netrin-1 & hepatocellular carcinoma hcc

Conditions: HCC

Summary: netrin-1 is a dependence receptor ligand participating in the pathology of several cancer types. it is up-regulated in chronic liver diseases, cirrhosis and hcc. we hypothesize that netrin-1 may play a detrimental role in hcc. the goal of this project is to characterize netrin-1 signals in hcc samples with ad hoc controls, to investigate the benefit of capturing netrin-1 in preclinical models of hcc and to try to define patients groups the most likely to benefit from this targeting approach in the clinic.


Eligibility criteria:
inclusion criteria: * any patient suffering from hcc * age \>18 * informed consent provided exclusion criteria: - absence of informed consent
safety study of bms-986165 in healthy subjects and to treat psoriasis

Conditions: Healthy Subjects

Summary: the purpose of this study is to establish if bms-986165 is safe and effective at treating autoimmune diseases. bms-986165 which has shown some promise in preclinical studies for inhibiting autoimmune conditions. this study will be the first time this drug is given to humans, and will be conducted entirely in healthy subjects. it will be run in 4 parts. part a will investigate single oral doses of drug. part b will investigate giving the drug daily for 14 days. part c will investigate daily doses for 14 days in healthy volunteers with japanese decent. part d will investigate whether food, stomach acidity or giving the drug in a capsule makes a difference to the safety and potential use of this drug.


Eligibility criteria:
for more information regarding bms clinical trial participation, please visit www.bmsstudyconnect.com inclusion criteria: * healthy male and female participants * 18 to 50 years of age (parts a-d) exclusion criteria: * participants that had recent infections * participants with low blood pressure or increased heart rate * participants with any chronic health related problems * participants with active cancer within the last 5 years * participants with any other major medical illness
comparative effects of intensive and distributed cimt on upper extremity function in stroke patients

Conditions: Stroke

Summary: the main question this clinical trial is aims to answer is whether intensive and distributed constraint-induced movement therapy has similar effects on upper extremity function in participants with stroke. participants will receive intensive protocol of cimt for 6 hours for 6 days to make total of 36 hours while distributed protocol participants will receive 2.25 hours of training two times a week for 8 weeks making total of 36 hours.

many studies have examined the effects of constraint-induced movement therapy (cimt) in upper extremity function in stroke patients. literature has shown effectiveness of different cimt protocols for stroke patients. emerging research have demonstrated comparative efficacy of constraint-induced movement therapy with different physical therapy approaches i.e. bimanual intensive training, motor relearning programme for improving upper extremity function. but according to researcher's knowledge, the gap of current knowledge is that no study has directly investigated the comparative effectiveness of intensive and distributed cimt in stroke patients and if intensive and distributed cimt had similar motor outcomes in upper limb function after stroke

Eligibility criteria:
inclusion criteria: * age 40-70 years * ischemic or hemorrhagic stroke * both genders eligible * gcs score ≥ 13 * able to extend at least 10° at the fingers * able to extend at least 20° at the wrist * patients diagnosed with one side more affected(hemiplegia) * modified ashworth scale score ≤2 exclusion criteria: * severe, chronic systemic illness * epilepsy * history of fall past 6 months * injections of botulinum toxin type a or operations on the ue within 6 months

Keywords: stroke upper extremity function
treatment of panic disorder via internet with a wireless temperature biofeedback ring

Conditions: Panic Disorder

Summary: internet plays a more and more important role in many applications of healthcare. many researches on the integrations of internet and mental health care have been proposed in recent years. this project aims at the development of an online treatment system which combines the biofeedback therapy and the web technologies to treat the patients suffering from panic disorder with partial response to medications. this project also evaluates the efficacy of a new- designed wireless temperature biofeedback ring.

the participants should be chronic panic patients. they login an web-based server and practice muscle relaxation on-line every day. there will be two two parallel groups: one group practicing muscle relaxation only and the other practicing muscle relaxation with finger surface temperature monitor through a wireless biofeedback ring.

Eligibility criteria:
inclusion criteria: 1. the participant must fulfill dsm-iv criteria for panic disorder. 2. the participant must be between 18 and 60 years of age. 3. the participant must have panic disorder as the primary problem. 4. if the participant is taking prescribed drugs for panic disorder, a) the dosage have to be constant for 2 months before starting treatment, and b) the participant have to agree to keep the dosage constant for 1 month after starting treatment. 5. if the participant was already in therapy, the contact must have lasted at least 6 months and not be based on cognitive behavior therapy. 6. all participants have access to a computer with an internet connection. exclusion criteria: 1. the participant suffers from any other psychiatric disorder in immediate need of treatment. 2. the participant fulfills dsm-iv criteria for major depression. 3. the participant has epilepsy, kidney problems, strokes, organic brain syndrome, emphysema, heart disorders, or chronic hypertension. 4. the participant has alcoholism.

Keywords: panic disorder temperature biofeedback internet
oestradiol pre-treatment in an ultrashort flare gnrh agonist/gnrh antagonist protocol in poor responders undergoing ivf

Conditions: Infertility

Summary: to evaluate the effect of oestradiol pre-treatment in a combined ultrashort flare gnrh agonist /gnrh antagonist protocol

the combined ultrashort flare gnrh agonist /gnrh antagonist protocol during coh cycle resulted in a significantly higher clinical pregnancy rate in patients with poor embryo quality, with repeated ivf failures and in poor responders. this is a protocol combining the effect of the microdose flare on endogenous fsh release with the benefit of an immediate lh suppression of the gnrh antagonist. a major disadvantage of the use of a gnrh antagonist protocol is the limitation for programming cycles, as the drugs administration is started on day 2 of the menstrual cycle and is strictly followed until the hcg criteria are met. the purpose of the study is to perform oestradiol pre-treatment with the combined ultrashort flare gnrh agonist /gnrh antagonist protocol aiming to 1. better programme an antagonist cycle and 2. improve the ivf outcome parameters, from the production of more follicles / oocytes up to the rise in live birth rates.

Eligibility criteria:
inclusion criteria: * patients with poor or no response in previous coh for ivf cycles * patients with amh \ 12 * poor quality of embryos in previous cycles * age of patients up to 44 years exclusion criteria: * patients with normal ovarian reserve * patients with sonographically detected hydrosalpinges * presence of intramural fibroid distorting the endometrial cavity or submucous myoma or asherman's syndrome * women with thrombofilia disorders

Keywords: ivf/icsi cycles, poor responders, ultrashort flare protocol, antagonist protocol
safety of lbh589 alone and in combination with intravenous docetaxel and prednisone

Conditions: Hormone Refractory Prostate Cancer Disease

Summary: this 2-arm study is designed to determine the maximum tolerated dose of lbh589 as a single agent and in combination with docetaxel and prednisone 5 mg twice daily (second arm) and to characterize the safety, tolerability, biologic activity and pharmacokinetic profile.


Eligibility criteria:
inclusion criteria: * patients with hormone refractory prostate cancer * patients must have metastatic disease with at least 1 measurable soft tissue lesion that can be assessed by ct or mri and/or detectable lesion(s) on bone scintigraphy scan. patients with only elevated psa levels are not eligible for entry. * patients must meet laboratory inclusion criteria defined in the protocol * patients must be able to provide written informed consent exclusion criteria: * patients with prior or concurrent brain metastases * impaired cardiac, gastrointestinal, kidney or liver function * use of therapeutic androgens other protocol-defined inclusion/exclusion criteria may apply

Keywords: lbh lbh589 prostate cancer hrpc
gma and peri in moderate-late preterms

Conditions: Preterm; Assessment; Risk Factor; Cerebral Palsy

Summary: to analyze the relationship between the early diagnosis of cerebral palsy with the risk factors of this pathology in moderate and late premature infants

analyze a sample of moderate and late premature infants using general movements and verify which of them would have an early diagnosis of cerebral palsy and relate it to their risk factors for this pathology.

Eligibility criteria:
inclusion criteria: * subjects who were born between the week 32 + 0 days and the week 36 + 6 days and who are admitted to the hospital nuestra señora del prado de talavera de la reina or the hospital virgen de la salud de toledo. exclusion criteria: * any type of pre and perinatal diagnostic neurological involvement. * any type of pathology associated with prematurity. * children who have prescribed any of the following medications (10): * barbiturates * antiepileptic * indomethacin * dexamethasone
impact of undernutrition in patients over 70 years of age thrombolysed and/or thrombectomized for stroke

Conditions: Stroke

Summary: undernutrition is a frequent problem in hospitals (at least 30% of patients, seneca-nhanes studies). its impact on morbidity and mortality is well known in gerontology, oncology and intensive care. there are very few neurovascular studies dealing with the consequences of undernutrition present before the stroke. indeed, most of the medical literature concerns only undernutrition acquired after a stroke. the investigator propose to analyze medical data from a cohort of patients over 70 years of age thrombolysed and/or thrombectomized in the neurovascular department between the years 2014 and 2019.


Eligibility criteria:
inclusion criteria: * patients over 70 years of age with cerebral infarction, thrombolysed and/or thrombectomized between 2014 and 2019, managed in the neurology and neurovascular department of the paris saint-joseph hospital * french-speaking patient exclusion criteria: * patients with non-thrombolyzed stroke * patient with a tia (transient ischemic attack) * patient under guardianship or curatorship * patient deprived of liberty * patient under court protection * patients who object to the use of their data for this research
a study of the safety and effectiveness of oral levofloxacin compared with oral ciprofloxacin in the treatment of adults with mild to moderate infections of the skin and the supportive layers beneath the skin

Conditions: Skin Diseases, Infectious; Cellulitis

Summary: the purpose of this study is to evaluate the safety and effectiveness of levofloxacin, an antibiotic, compared with ciprofloxacin, another antibiotic, in the treatment of adults with mild to moderate infections of the skin and the supportive layers beneath the skin.

levofloxacin is an antibacterial agent used for the treatment of many types of infections in adults. this is a randomized, open-label, parallel group, multicenter study to determine the safety and effectiveness of levofloxacin (500 mg by mouth once daily for 7-10 days) compared with another frequently used antibiotic, ciprofloxacin (500 mg by mouth every 12 hours for 7 -10 days), in adults with mild to moderate infections of the skin and the supportive layers beneath the skin. the study consists of 3 visits: one visit \[pre-therapy\] for screening and enrollment, and two visits to assess safety and effectiveness (one visit \[on-therapy\] on days 3 - 5 of the study and one visit \[post-therapy\] 2 - 7 days after the last dose of the study drug). the total duration of patient participation in the study is approximately 2 weeks. the primary assessments of effectiveness include the clinical response to treatment (defined at post-therapy as cured, improved or failed) and the microbiological response at post-therapy (the rate of eradication of the disease-causing bacteria, determined by patient and by type of bacteria). safety evaluations (incidence of adverse events, physical examination, physical examination of the skin, and laboratory tests) are performed throughout the study. the study hypothesis is that treatment with levofloxacin is at least as effective and as well tolerated as treatment with ciprofloxacin in patients with mild to moderate infections of the skin and the supportive layers beneath the skin. levofloxacin 500 mg by mouth once daily, or ciprofloxacin 500 mg by mouth every 12 hours. the duration of treatment is 7 to 10 days.

Eligibility criteria:
inclusion criteria: * diagnosis of mild to moderate infection of the skin and/or the supportive layers beneath the skin, as indicated by pain at the site of the infection, redness, drainage, swelling, or other relevant clinical signs * tissue sample available from the area of the skin affected by the bacteria * able to take medication by mouth exclusion criteria: * patients with a condition requiring treatment with antibiotics by injection into a vein, a muscle, or beneath the skin * having a severe infection * previous allergic or serious adverse reactions to similar antibiotics * taken antibiotics internally within 48 hours of the start of the study with resulting improvement * require a second antibiotic taken internally or need an antibiotic applied directly to the site of the infection in addition to the study drug

Keywords: infectious skin diseases skin diseases bacterial skin diseases cellulitis quinolones levofloxacin